



**Approved January 23, 2014**

## **A Randomized, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Circadin® To Alleviate Sleep Disturbances In Children With Neurodevelopmental Disabilities**

This research study is being conducted by centers across the United States to help determine if Circadin is a safe and effective treatment to alleviate sleep disturbances in children with neurodevelopmental disabilities. Kennedy Krieger Institute is looking for children ages 2 through 17.5 years, to participate in this study. The study involves up to 10 visits to Kennedy Krieger Institute over 112 weeks. There are no direct medical benefits for participating in this study. All testing is done at no cost to the participant and parking is free.

For more information about this study, please contact the Study Coordinator at (443) 923-3850

or by email at [ResearchTrials@kennedykrieger.org](mailto:ResearchTrials@kennedykrieger.org)

PI: Robert Findling, M.D., M.B.A.

Protocol #: NA\_00089733

[www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT01906866)

The Sponsor for this study is Neurim Pharmaceuticals